Details for Patent: 10,076,555

Which drugs does patent 10,076,555 protect, and when does it expire?

Patent 10,076,555 protects SCENESSE and is included in one NDA.

This patent has eleven patent family members in ten countries.

Summary for Patent: 10,076,555

Patent landscape, scope, and claims:

Title:	Methods of inducing melanogenesis in a subject
Abstract:	Described herein are methods and compositions for inducing melanogenesis in a human subject. The method comprises administering to a subject an alpha-MSH analogue, in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of subject without inducing homologous desensitization of the melanocortin-1 receptors.
Inventor(s):	Kleinig; Michael John (Brunswick, AU), Tice; Thomas R. (Indian Springs, AL), Staas; Jay K. (Marylene, AL)
Assignee:	Clinuvel Pharmaceuticals Limited (Melbourne, AU)
Application Number:	15/135,241
Patent Claim Types: see list of patent claims	Use; Formulation; Delivery;

Drugs Protected by US Patent 10,076,555

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Clivunel Inc	SCENESSE	afamelanotide	IMPLANT;SUBCUTANEOUS	210797-001	Oct 8, 2019		RX	Yes	Yes	10,076,555					INCREASE PAIN-FREE LIGHT EXPOSURE IN ADULT PATIENTS WITH A HISTORY OF PHOTOTOXIC REACTIONS FROM ERYTHROPOIETIC PROTOPORPHYRIA (EPP)

International Family Members for US Patent 10,076,555

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2005269244
Canada	2575866
China	101076314